AlphaCentric Advisors LLC Purchases Shares of 18,667 Boston Scientific Co. (NYSE:BSX)

AlphaCentric Advisors LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 18,667 shares of the medical equipment provider's stock, valued at approximately $1,667,000. Boston Scientific makes up 1.7% of AlphaCentric Advisors LLC's holdings, making the stock its 15th largest position.

Several other hedge funds also recently modified their holdings of the company. Creative Planning increased its holdings in shares of Boston Scientific by 7.7% in the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider's stock valued at $17,113,000 after purchasing an additional 14,663 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Boston Scientific by 11.5% in the third quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider's stock valued at $366,000 after purchasing an additional 449 shares in the last quarter. Stratos Wealth Advisors LLC increased its holdings in shares of Boston Scientific by 8.9% in the third quarter. Stratos Wealth Advisors LLC now owns 6,419 shares of the medical equipment provider's stock valued at $538,000 after purchasing an additional 522 shares in the last quarter. Net Worth Advisory Group acquired a new stake in shares of Boston Scientific in the third quarter valued at approximately $373,000. Finally, Moss Adams Wealth Advisors LLC acquired a new stake in shares of Boston Scientific in the third quarter valued at approximately $256,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

BSX has been the subject of a number of research reports. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, January 29th. Barclays raised their price objective on shares of Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Royal Bank of Canada raised their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Sanford C. Bernstein raised their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Finally, Wells Fargo & Company raised their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $107.39.

Boston Scientific Stock Down 0.2 %

BSX stock traded down $0.26 during midday trading on Thursday, hitting $105.41. The company's stock had a trading volume of 5,977,501 shares, compared to its average volume of 6,049,724. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a twelve month low of $65.33 and a twelve month high of $107.17. The company's fifty day moving average price is $97.39 and its 200 day moving average price is $88.94. The stock has a market capitalization of $155.36 billion, a P/E ratio of 84.33, a PEG ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, equities research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling

In other news, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the transaction, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 153,640 shares of company stock valued at $15,718,289. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.